Theodore Alan  Huizenga net worth and biography

Theodore Huizenga Biography and Net Worth

Mr. Theodore Huizenga is the CAO of Ultragenyx Pharmaceutical. He is 52 years old.

What is Theodore Alan Huizenga's net worth?

The estimated net worth of Theodore Alan Huizenga is at least $959,200.68 as of September 7th, 2023. Mr. Huizenga owns 23,614 shares of Ultragenyx Pharmaceutical stock worth more than $959,201 as of December 11th. This net worth approximation does not reflect any other assets that Mr. Huizenga may own. Learn More about Theodore Alan Huizenga's net worth.

How old is Theodore Alan Huizenga?

Mr. Huizenga is currently 52 years old. There are 7 older executives and no younger executives at Ultragenyx Pharmaceutical. The oldest executive at Ultragenyx Pharmaceutical is Dr. Emil D. Kakkis M.D., Ph.D., Founder, President, CEO & Director, who is 63 years old. Learn More on Theodore Alan Huizenga's age.

How do I contact Theodore Alan Huizenga?

The corporate mailing address for Mr. Huizenga and other Ultragenyx Pharmaceutical executives is 60 Leveroni Court, Novato CA, 94949. Ultragenyx Pharmaceutical can also be reached via phone at (415) 483-8800 and via email at [email protected]. Learn More on Theodore Alan Huizenga's contact information.

Has Theodore Alan Huizenga been buying or selling shares of Ultragenyx Pharmaceutical?

Theodore Alan Huizenga has not been actively trading shares of Ultragenyx Pharmaceutical during the past quarter. Most recently, Theodore Alan Huizenga sold 2,163 shares of the business's stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $40.80, for a transaction totalling $88,250.40. Following the completion of the sale, the chief accounting officer now directly owns 23,614 shares of the company's stock, valued at $963,451.20. Learn More on Theodore Alan Huizenga's trading history.

Who are Ultragenyx Pharmaceutical's active insiders?

Ultragenyx Pharmaceutical's insider roster includes William Aliski (Director), Camille Bedrosian (EVP), Mardi Dier (CFO), Erik Harris (EVP), Dennis Huang (EVP), Theodore Huizenga (CAO), Emil Kakkis (CEO), Thomas Kassberg (EVP), Karah Parschauer (EVP), John Pinion (Insider), Corsee Sanders (Director), Shalini Sharp (CFO), and Clay Siegall (Director). Learn More on Ultragenyx Pharmaceutical's active insiders.

Are insiders buying or selling shares of Ultragenyx Pharmaceutical?

During the last twelve months, insiders at the biopharmaceutical company sold shares 14 times. They sold a total of 112,569 shares worth more than $3,990,033.61. The most recent insider tranaction occured on October, 23rd when EVP Thomas Richard Kassberg sold 39,878 shares worth more than $1,307,200.84. Insiders at Ultragenyx Pharmaceutical own 6.8% of the company. Learn More about insider trades at Ultragenyx Pharmaceutical.

Information on this page was last updated on 10/23/2023.

Theodore Alan Huizenga Insider Trading History at Ultragenyx Pharmaceutical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/7/2023Sell2,163$40.80$88,250.4023,614View SEC Filing Icon  
9/1/2023Sell970$37.15$36,035.5023,777View SEC Filing Icon  
2/28/2023Sell639$43.40$27,732.6015,558View SEC Filing Icon  
12/21/2022Sell2,031$43.96$89,282.7616,197View SEC Filing Icon  
4/16/2022Sell132$84.55$11,160.6016,914View SEC Filing Icon  
10/14/2021Sell140$81.14$11,359.60View SEC Filing Icon  
5/6/2021Sell142$113.67$16,141.14View SEC Filing Icon  
3/8/2021Sell3,000$120.69$362,070.00View SEC Filing Icon  
3/1/2021Sell732$138.17$101,140.4417,276View SEC Filing Icon  
1/7/2021Sell4,000$140.65$562,600.0020,436View SEC Filing Icon  
10/14/2020Sell146$87.98$12,845.08View SEC Filing Icon  
7/8/2020Sell2,638$91.00$240,058.0016,582View SEC Filing Icon  
7/1/2020Sell2,611$81.00$211,491.0017,220View SEC Filing Icon  
5/26/2020Sell260$74.93$19,481.8018,591View SEC Filing Icon  
5/15/2020Sell2,461$71.00$174,731.0018,719View SEC Filing Icon  
1/14/2020Sell1,000$61.00$61,000.00View SEC Filing Icon  
6/15/2018Sell955$83.70$79,933.5012,895View SEC Filing Icon  
6/13/2018Sell1,338$76.97$102,985.86View SEC Filing Icon  
5/26/2017Sell480$57.46$27,580.809,366View SEC Filing Icon  
3/9/2017Sell2,500$86.34$215,850.00View SEC Filing Icon  
12/18/2015Sell1,500$110.55$165,825.002,500View SEC Filing Icon  
6/17/2015Sell1,500$94.80$142,200.00View SEC Filing Icon  
See Full Table

Theodore Alan Huizenga Buying and Selling Activity at Ultragenyx Pharmaceutical

This chart shows Theodore Alan Huizenga's buying and selling at Ultragenyx Pharmaceutical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ultragenyx Pharmaceutical Company Overview

Ultragenyx Pharmaceutical logo
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
Read More

Today's Range

Now: $40.62
Low: $39.42
High: $41.05

50 Day Range

MA: $36.69
Low: $31.73
High: $42.01

2 Week Range

Now: $40.62
Low: $31.52
High: $54.98


953,248 shs

Average Volume

699,986 shs

Market Capitalization

$3.34 billion

P/E Ratio


Dividend Yield